received the rsv vaccine now again in December of 2024; This non-serious case was reported by a consumer via call center representative and described the occurrence of extra dose administered in a elderly male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Previously administered products included Arexvy (Received 1st dose on September of 2022). In DEC-2024, the patient received Arexvy. In DEC-2024, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: received the rsv vaccine now again in December of 2024). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 02-JAN-2025 The reporter reported that patient received Arexvy vaccine second dose again in December of 2024 which led to extra dose administered. It was in error. The patient wanted to know if there were any harmful side effects from double dosing.